Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)

v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)
$ in Thousands
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Gain (loss) [Member]
Accumulated Deficit [Member]
Total
Balance, at beginning at Dec. 31, 2018     $ 212,157 $ (41) $ (188,452) $ 23,664
Balance, at beginning (in shares) at Dec. 31, 2018 9,856 328,689        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon conversion of Series A Convertible preferred stock   $ 1 (1)      
Issuance of common stock upon conversion of Series A Convertible preferred stock (in shares) (9,856) 281,610        
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per shares)     70     70
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share) (in shares)   2,000        
Employee stock purchase plan     3     3
Employee stock purchase plan (in shares)   177        
Stock-based compensation     305     305
Foreign currency transaction gain (loss)       2   2
Net loss         (6,233) (6,233)
Balance, at end at Mar. 31, 2019   $ 1 212,534 (39) (194,685) 17,811
Balance, at end (in shares) at Mar. 31, 2019   612,476        
Balance, at beginning at Dec. 31, 2018     212,157 (41) (188,452) 23,664
Balance, at beginning (in shares) at Dec. 31, 2018 9,856 328,689        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss           (19,911)
Balance, at end at Sep. 30, 2019   $ 2 218,258 (42) (208,363) 9,855
Balance, at end (in shares) at Sep. 30, 2019   1,575,246        
Balance, at beginning at Mar. 31, 2019   $ 1 212,534 (39) (194,685) 17,811
Balance, at beginning (in shares) at Mar. 31, 2019   612,476        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under 2018 Purchase Agreement     387     387
Issuance of common stock under 2018 Purchase Agreement (in shares)   22,754        
Issuance of common stock under At-the-market offering, net of transactional expenses of $1     33     33
Issuance of common stock under At-the-market offering, net of transactional expenses of $1 (in shares)   2,106        
Stock-based compensation     431     431
Net loss         (5,840) (5,840)
Balance, at end at Jun. 30, 2019   $ 1 213,385 (39) (200,525) 12,822
Balance, at end (in shares) at Jun. 30, 2019   637,336        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock under July 2019 Financing, net of transactional expenses of $484   $ 1 4,483     4,484
Issuance of common stock under July 2019 Financing, net of transactional expenses of $484 (in shares)   900,000        
Issuance of commitment shares in August 2019 under 2019 Purchase Agreement   $ 35,529        
Employee stock purchase plan     28     28
Employee stock purchase plan (in shares)   2,381        
Stock-based compensation     362     362
Foreign currency transaction gain (loss)       (3)   (3)
Net loss         (7,838) (7,838)
Balance, at end at Sep. 30, 2019   $ 2 218,258 (42) (208,363) 9,855
Balance, at end (in shares) at Sep. 30, 2019   1,575,246        
Balance, at beginning at Dec. 31, 2019   $ 9 226,524 (46) (217,070) 9,417
Balance, at beginning (in shares) at Dec. 31, 2019   8,531,504        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share)   $ 13 7,461     7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares)   13,111,999        
Deemed dividend in connection with repricing of November 2019 warrants     451     451
Warrant deemed dividend     (451)     (451)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)     4,602     4,602
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares) 5,313          
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock     1,260     1,260
Preferred stock deemed dividend     (1,260)     (1,260)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292)   $ 4 1,891     1,895
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) (in shares)   3,837,000        
Issuance of common stock upon conversion of Series A Convertible preferred stock   $ 9 (9)      
Issuance of common stock upon conversion of Series A Convertible preferred stock (in shares) (5,313) 9,321,053        
Issuance of common stock in March 2020   $ 14 14,770     14,784
Issuance of common stock in March 2020 (in shares)   14,550,000        
Employee stock purchase plan     2     2
Employee stock purchase plan (in shares)   1,578        
Stock-based compensation     360     360
Foreign currency transaction gain (loss)       (14)   (14)
Net loss         (7,273) (7,273)
Balance, at end at Mar. 31, 2020   $ 49 255,601 (60) (224,343) 31,247
Balance, at end (in shares) at Mar. 31, 2020   49,353,134        
Balance, at beginning at Dec. 31, 2019   $ 9 226,524 (46) (217,070) 9,417
Balance, at beginning (in shares) at Dec. 31, 2019   8,531,504        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Preferred stock deemed dividend           (1,260)
Net loss           (33,442)
Balance, at end at Sep. 30, 2020   $ 140 313,004 (64) (250,512) 62,568
Balance, at end (in shares) at Sep. 30, 2020   140,159,546        
Balance, at beginning at Mar. 31, 2020   $ 49 255,601 (60) (224,343) 31,247
Balance, at beginning (in shares) at Mar. 31, 2020   49,353,134        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in June 2020 under the equity line   $ 1 277     278
Issuance of common stock in June 2020 under the equity line (in shares)   464,471        
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131   $ 53 34,089     34,142
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 (in shares)   52,986,301        
Issuance of common stock in the acquisition of Trigemina assets   $ 2 1,358     1,360
Issuance of common stock in the acquisition of Trigemina assets (in shares)   2,000,000        
Stock-based compensation     733     733
Foreign currency transaction gain (loss)       (9)   (9)
Net loss         (14,179) (14,179)
Balance, at end at Jun. 30, 2020   $ 105 292,058 (69) (238,522) 53,572
Balance, at end (in shares) at Jun. 30, 2020   104,803,906        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock in July 2020, net of transaction expenses of $829   $ 21 9,620     9,641
Issuance of common stock in July 2020, net of transaction expenses of $829 (in shares)   20,940,000        
Issuance of common stock in September 2020 under At-the-market offering, net of transactional expenses of $267   $ 9 7,997     8,006
Issuance of common stock in September 2020 under At-the-market offering, net of transactional expenses of $267 (in shares)   9,282,236        
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see Note 9)   $ 5 2,417     2,422
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see Note 9) (in shares)   4,533,404        
Issuance of committment shares under 2020 Purchase Agreement (in shares)   600,000        
Stock-based compensation     912     912
Foreign currency transaction gain (loss)       5   5
Net loss         (11,990) (11,990)
Balance, at end at Sep. 30, 2020   $ 140 $ 313,004 $ (64) $ (250,512) $ 62,568
Balance, at end (in shares) at Sep. 30, 2020   140,159,546